Discordance of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in non-small cell lung cancer

Chinese Journal of Lung Cancer

Volumn 14, Issue 6, 2011, Pages 518-522

  Fang, Qin ^a   Zhang, Liang ^a   Wang, Siyu ^a   Ou, Wei ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Corresponding metastases; Epidermal growth factor receptor; Lung neoplasms; Primary tumor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79958704516     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2011.06.07     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin, 2008, 58(2): 71-96.
2. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New Engl J Med, 2002, 346(2): 92-98.
3. Chana SK, Gullicka WJ, Hill ME, et al. Mutations of the epidermal growth factor receptor in non-small cell lung cancer - Search and destroy. Eur J Cancer, 2006, 42(1): 17-23.
4. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA, 2003, 290(16): 2149-2158.
5. Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol, 2004, 22(16): 3238-3247.
6. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 2009, 361(10): 947-957.
7. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol, 2010, 11(2): 121-128.
8. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 2010, 362(25): 2380-2388.
9. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 2004, 350(21): 2129-2139.
10. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA, 2004, 101(36): 13306-13311.
11. Tamura K, Okamoto I, Kashii T, et al. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer, 2008, 98(5): 907-914.
12. Morita S, Okamoto I, Kobayashi K, et al. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res, 2009, 15(13): 4493-4498.
13. Jackman DM, Miller VA, Cioff Redi LA, et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previouslyuntreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res, 2009, 15(19): 5267-5273.
14. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med, 2009, 361(10): 958-967.
15. Asahina H, Yamazaki K, Kinoshita I, et al. A phase II trial of gefitinib as firstline therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer, 2006, 95(8): 998-1004.
16. Sutani A, Nagai Y, Udagawa K, et al. Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J Cancer, 2006, 95(11): 1483-1489.
17. Park S, Holmes-Tisch AJ, Cho EY, et al. Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. J Thorac Oncol, 2009, 4(7): 809-815.
18. Gow CH, Chang YL, Hsu YC, et al. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann Oncol, 2009, 20(4): 696-702.
19. Gomez-Roca C, Raynaud CM, Penault-Llorca F, et al. Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites. J Thorac Oncol, 2009, 4(10): 1212-1220.
20. Kalikaki A, Koutsopoulos A, Trypaki M, et al. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer, 2008, 99(6): 923-929.
21. Detterbeck FC, Boffa DJ, Tanoue LT, et al. The new lung cancer staging system. Chest, 2009, 136(1): 260-271.
22. Beasley MB, Brambilla E, Travis WD, et al. The 2004 World Health Organization classification of lung tumors. Semin Roentgenol, 2005, 40(2): 90-97.
23. Endo K, Konishi A, Sasaki H, et al. Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast Taq Man PCR assay. Lung Cancer, 2005, 50(3): 375-384.
24. Huang S, Liu F, Sha Z, et al. Effect of high glucose, angiotensin II and receptor antagonist losartan on the expression of connective tissue growth factor in cultured mesangial cells. Chin Med J, 2003, 116(4): 554-557.
25. Matsumoto S, Takahashi K, Iwakawa R, et al. Frequent EGFR mutations in brain metastases of lung adenocarcinoma. Int J Cancer, 2006, 119(6): 1491-1494.
26. Takahashi K, Kohno T, Matsumoto S, et al. Clonal and parallel evolution of primary lung cancers and their metastases revealed by molecular dissection of cancer cells. Clin Cancer Res, 2007, 13(1): 111-120.